Friday, February 23, 2024
BestWooCommerceThemeBuilttoBoostSales-728x90

Personalized medicine offers hope for millions with inflammatory bowel disease



The prevalence of inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), is rapidly increasing worldwide, affecting an estimated 6.8 million people. This surge brings significant economic burdens, with annual healthcare costs exceeding $12,000 and $7,000 for CD and UC patients, respectively. Tailored drug selection based on individual factors can potentially reduce these costs and improve patient outcomes.

Factors associated with a Western lifestyle such as urbanization, high animal protein intake, ultra-processed foods, and reduced fiber consumption are linked to IBD onset. Gut microbial diversity also plays a key role, with rural communities exhibiting greater microbial richness compared to urban populations. Understanding these environmental and microbial influences is crucial for developing preventive strategies.

Despite significant scientific advancements, the exact causes of UC and CD remain elusive. A complex interplay of genetics, immune dysregulation, gut microbiota alterations, and environmental factors contributes to disease development. Current immunosuppressive treatment options require more personalized approaches.

The field of precision medicine offers hope for personalized IBD treatment. We can potentially predict treatment response and optimize therapy selection by analyzing individual genetic, immunological, and microbial profiles. This “multiomics” approach, coupled with machine learning, holds the key to unlocking new therapeutic targets and improving patient outcomes.

This review dives deeper into IBD’s genetic, immunological, and microbial drivers, highlighting potential predictive markers of treatment response. We explore the principles of machine-learning-powered bioinformatics and collaborative research, paving the way for future precision medicine strategies in IBD. By embracing personalized approaches, we can unlock a brighter future for patients living with this chronic condition.

Source:

Journal reference:

Little, R. D., et al. (2024). Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions. eGastroenterology. doi.org/10.1136/egastro-2023-100006.



Source link

Related Articles

Leave a Reply

[td_block_social_counter facebook="beingmedicos1" twitter="being_medicos" youtube="beingmedicosgroup" style="style8 td-social-boxed td-social-font-icons" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjM4IiwiZGlzcGxheSI6IiJ9LCJwb3J0cmFpdCI6eyJtYXJnaW4tYm90dG9tIjoiMzAiLCJkaXNwbGF5IjoiIn0sInBvcnRyYWl0X21heF93aWR0aCI6MTAxOCwicG9ydHJhaXRfbWluX3dpZHRoIjo3Njh9" custom_title="Stay Connected" block_template_id="td_block_template_8" f_header_font_family="712" f_header_font_transform="uppercase" f_header_font_weight="500" f_header_font_size="17" border_color="#dd3333"]
- Advertisement -spot_img

Latest Articles